SCHEMBL29968158

SCHEMBL29968158

Cc1n[nH]c2ncc(CN3CCc4ccc(C(=O)Nc5cc(CN6CCN(C)CC6)nc(C(F)(F)F)c5)cc43)cc12

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 13/20 0.42
▸ EGFR P00533 4/20 0.42
▸ BRAF P15056 4/20 0.42
▸ DDR2 Q16832 6/20 0.42
▸ DDR1 Q08345 5/20 0.42
▸ BCR P11274 8/20 0.42
▸ KIT P10721 1/20 0.42
▸ FGFR1 P11362 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ PDGFRA P16234 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ FLT3 P36888 1/20 0.41
▸ LRRK2 Q5S007 1/20 0.41
▸ HDAC6 Q9UBN7 1/20 0.41
▸ NTRK1 P04629 1/20 0.40
▸ NTRK3 Q16288 1/20 0.40
▸ NTRK2 Q16620 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27081835 1.00 ABL1 (0.42) ABL1EGFRBRAFDDR2DDR1
SCHEMBL27081410 0.90 TNF (0.36) ABL1EGFRBRAFDDR2DDR1
SCHEMBL27082974 0.90 ABL1 (0.45) ABL1EGFRBRAFDDR2DDR1
SCHEMBL27082978 0.90 ABL1 (0.45) ABL1EGFRBRAFDDR2DDR1
SCHEMBL29968090 0.88 DDR2 (0.56) ABL1DDR2DDR1BCRKIT
SCHEMBL27081787 0.88 DDR2 (0.56) ABL1DDR2DDR1BCRKIT
SCHEMBL29967913 0.85 ABL1 (0.58) ABL1EGFRBRAFBCRKIT
SCHEMBL29967998 0.85 DDR2 (0.45) ABL1DDR2DDR1BCRKIT
SCHEMBL27082011 0.85 DDR2 (0.45) ABL1DDR2DDR1BCRKIT
SCHEMBL27081498 0.85 ABL1 (0.58) ABL1EGFRBRAFBCRKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4313972-B1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARM SPA (IT) 2025-01-29 — — EP claimed
EP-4313972-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2024-02-07 — — EP claimed
CN-117062812-A Indoline derivatives as DDR inhibitors 奇斯药制品公司 2023-11-14 — — CN claimed
WO-2022200577-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2022-09-29 — — WO claimed
EP-4313972-B1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARM SPA (IT) 2025-01-29 — — EP disclosed
US-20240217967-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-07-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240217967-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS DDR1, DDR2, DDRGK1 ABL1 284/4885EGFR 105/4885BRAF 799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback